Patents by Inventor Jennifer Dumont

Jennifer Dumont has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AUTOMATIC PROJECT PLANNING, BUDGETING, AND TRACKING TOOL
    Publication number: 20230376903
    Abstract: A facility for tracking a planned project is described. The facility initializes a project-tracking data object, and responds to user input by assembling in the data object a hierarchical model of the project, from project elements each having one of a plurality of element types. The facility persistently stores the data object containing the assembled model.
    Type: Application
    Filed: May 17, 2022
    Publication date: November 23, 2023
    Inventors: Jennifer Dumont, Bert Martin, Terri Trobridge
  • FACTOR VIII-FC CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF
    Publication number: 20220265780
    Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: January 28, 2022
    Publication date: August 25, 2022
    Inventors: Jennifer A. DUMONT, Susan LOW, Alan J. BITONTI, Glenn PIERCE, Alvin LUK, Haiyan JIANG, Byron MCKINNEY, Matt OTTMER, Jurg SOMMER, Karen NUGENT, Lian LI, Robert PETERS
  • Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereof
    Patent number: 11266720
    Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: March 8, 2022
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert Peters
  • FACTOR VIII CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF
    Publication number: 20210220476
    Abstract: The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: December 4, 2020
    Publication date: July 22, 2021
    Inventors: Jennifer A. DUMONT, Susan LOW, Alan J. BITONTI, Glenn PIERCE, Alvin LUK, Haiyan JIANG, Byron MCKINNEY, Matt OTTMER, Jurg SOMMER, Karen NUGENT, Lian LI, Robert T. PETERS
  • Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
    Patent number: 10881742
    Abstract: The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: January 5, 2021
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert T. Peters
  • METHODS OF INDUCING IMMUNE TOLERANCE TO CLOTTING FACTORS
    Publication number: 20200085915
    Abstract: The present disclosure provides methods inducing immune tolerance in a human, comprising administering to the human an effective amount of a composition or a chimeric protein comprising a clotting factor and an Fc region.
    Type: Application
    Filed: December 1, 2017
    Publication date: March 19, 2020
    Inventors: Jennifer DUMONT, Nisha JAIN, Stefan LETHAGEN
  • METHODS OF TREATING HEMOPHILIC ARTHROPATHY USING CHIMERIC CLOTTING FACTORS
    Publication number: 20190381149
    Abstract: The present disclosure provides methods treating reversible hemophilic arthropathy of a joint in a human having hemophilia comprising administering to the human an effective amount of a chimeric protein or composition comprising a clotting factor and an Fc region.
    Type: Application
    Filed: December 1, 2017
    Publication date: December 19, 2019
    Inventors: Jennifer DUMONT, Nisha JAIN, Desilu GLAZEBROOK
  • FACTOR VIII-FC CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF
    Publication number: 20190262429
    Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII: polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: February 7, 2019
    Publication date: August 29, 2019
    Inventors: Jennifer A. DUMONT, Susan LOW, Alan J. BITONTI, Glenn PIERCE, Alvin LUK, Haiyan JIANG, Byron MCKINNEY, Matt OTTMER, Jurg SOMMER, Karen NUGENT, Lian LI, Robert PETERS
  • CELL LINE EXPRESSING SINGLE CHAIN FACTOR VIII POLYPEPTIDES AND USES THEREOF
    Publication number: 20190010212
    Abstract: The present invention provides cell lines for producing single chain FVIII polypeptides, e.g., chimeric single chain FVIII polypeptides, methods of producing single chain FVIII polypeptides, single chain FVIII polypeptides, and methods of treating Hemophilia A with a single chain Factor VIII polypeptide.
    Type: Application
    Filed: June 12, 2018
    Publication date: January 10, 2019
    Applicant: Bioverativ Therapeutics Inc.
    Inventors: Susan Low, Jennifer A. Dumont, Alan J. Bitonti
  • FACTOR VIII CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF
    Publication number: 20180360982
    Abstract: The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: May 29, 2018
    Publication date: December 20, 2018
    Applicant: Bioverativ Therapeutics Inc.
    Inventors: Jennifer A. DUMONT, Susan LOW, Alan J. BITONTI, Glenn PIERCE, Alvin LUK, Haiyan JIANG, Byron MCKINNEY, Matt OTTMER, Jurg SOMMER, Karen NUGENT, Lian LI, Robert T. PETERS
  • Cell line expressing single chain factor VIII polypeptides and uses thereof
    Patent number: 10023628
    Abstract: The present invention provides cell lines for producing single chain FVIII polypeptides, e.g., chimeric single chain FVIII polypeptides, methods of producing single chain FVIII polypeptides, single chain FVIII polypeptides, and methods of treating Hemophilia A with a single chain Factor VIII polypeptide.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: July 17, 2018
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Susan Low, Jennifer A. Dumont, Alan J. Bitonti
  • Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
    Patent number: 10010622
    Abstract: The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: July 3, 2018
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitoni, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert Peters
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20160222110
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: December 29, 2015
    Publication date: August 4, 2016
    Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20160222109
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: December 29, 2015
    Publication date: August 4, 2016
    Applicants: Dyax Corp., Biogen Hemophilia Inc.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20160222111
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: December 30, 2015
    Publication date: August 4, 2016
    Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20160222108
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: December 22, 2015
    Publication date: August 4, 2016
    Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20160222112
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: December 30, 2015
    Publication date: August 4, 2016
    Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use Thereof
    Publication number: 20160199455
    Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: December 9, 2015
    Publication date: July 14, 2016
    Applicant: Biogen Hemophilia Inc.
    Inventors: Jennifer A. DUMONT, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert Peters
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20160194397
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: December 31, 2015
    Publication date: July 7, 2016
    Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • Antibodies to FeRn and uses thereof
    Patent number: 9260520
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: February 16, 2016
    Assignees: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James McGivney, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan